SingleLongevity

PNC-27 30mg

Preclinical chimeric peptide targeting HDM-2 on cell membranes, investigated for membrane-lytic activity in oncological models.

Mechanism

PNC-27 interacts with cell-surface HDM-2 complexes to induce transmembrane pore formation, triggering selective membranolysis and rapid necrotic cell death in target cells.

Dosing

Standard laboratory titration protocols cite an initial exploratory dose of 100 mcg administered once daily.

Reconstitution

Reconstituting a 30 mg vial with 3.0 mL of bacteriostatic water yields a clean solution with an active concentration of 10 mg/mL (10,000 mcg/mL).

Storage

Store the unmixed lyophilized powder frozen at -20 °C, and once reconstituted, keep the solution refrigerated at 2–8 °C away from light without refreezing.

Mix & measure PNC-27 30mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure PNC-27 30mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration10.0mg/mL

Draw volume0.010mL

On the syringe1.00units

Total doses in vial: 300.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	100 mcg (1× daily)	1 unit (0.01 mL)
Weeks 3–4	200 mcg (1× daily)	2 units (0.02 mL)
Weeks 5–8	300 mcg (1× daily)	3 units (0.03 mL)
Weeks 9–12	400 mcg (1× daily)	4 units (0.04 mL)
Weeks 13–16	500 mcg (1× daily)	5 units (0.05 mL)

Reconstitution Steps

1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
2
Release the diluent slowly down the vial's interior glass wall to minimize agitation and foaming.
3
Gently rotate or roll the vial until the lyophilized cake is fully dissolved without shaking.
4
Affix a label indicating the reconstitution date and 10 mg/mL concentration, then store in refrigeration at 2–8 °C protected from direct light.

Supplies Needed

Peptide Vial

PNC-27 30 mg lyophilized powder vial for experimental preparation

Insulin Syringes (U-100)

1 mL U-100 sterile syringes for precise measurement of low-volume aliquots

Bacteriostatic Water

3.0 mL sterile diluent containing benzyl alcohol used to dissolve the peptide

Alcohol Swabs

Used for aseptic wiping of vial rubber stoppers and surface preparation

Why researchers study it

Anticancer research

Membranolytic mechanism

p53 pathway research

Tumor-cell selectivity

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

PNC-27 is an experimental 32-amino-acid synthetic construct engineered by attaching a cell-penetrating leader domain to an HDM-2-binding sequence derived from the p53 tumor-suppressor protein. In laboratory settings, it is evaluated strictly as an investigational agent to study structural biology and cellular interaction mechanisms. It is not approved for therapeutic administration in humans. Preclinical research primarily focuses on how this chimeric structure interacts with anomalous membrane targets. By attaching to abnormally expressed HDM-2 on target cell surfaces, the peptide forms pores that lead to cell lysis, differentiating its pathway from traditional apoptosis. Despite exploratory findings in cell and rodent assays, regulatory agencies have issued explicit warnings highlighting that PNC-27 lacks human safety validation, is unapproved, and has previously faced safety risks including manufacturing contamination.

References

1.Journal of Biomedical Science, 2017 — Review of therapeutic peptides; PNC-27 mechanism and cancer-cell selectivity
2.Cancer Chemotherapy and Pharmacology, 2010 — PNC-27 induces tumor-cell membrane lysis; preclinical mechanism study
3.FDA Consumer Safety Communication — Warning: PNC-27 products are unapproved, unproven, and tested samples were contaminated
4.International Journal of Cancer, 2006 — PNC-28 (related peptide) blocks pancreatic cancer growth in vivo; mouse model study
5.BMC Cancer, 2008 — PNC-27 selectively kills cancer cells via HDM-2 binding and membrane disruption
6.PubMed, 2012 — PNC-27 peptide induces necrosis via a direct membrane-lysis mechanism